Skip to main content

Table 2 Univariable and Multivariable Analyses of cancer-specific survival in the Ttraining set

From: Nomograms for predicting survival in patients with micropapillary bladder cancer: a real-world analysis based on the surveillance, epidemiology, and end results database and external validation in a tertiary center

Subject characteristics

Univariate

Multivariate

HR (95% CI)

p value

HR (95% CI)

p value

Age (year), n (%)

    

 < 80

1 (reference)

1.000

1 (reference)

1.000

 >  = 80

1.81 (1.27–2.58)

0.001

2.62 (1.80, 3.82)

< 0.001

Race, n (%)

    

 Black

1 (reference)

1.000

1 (reference)

 

 White

0.70 (0.40–1.24)

0.223

–

–

 Othera

0.40 (0.15–1.06)

0.066

–

–

Sex, n (%)

    

 Female

1 (reference)

1.000

1 (reference)

1.000

 Male

0.70 (0.50–1.00)

0.047

0.90 (0.62, 1.29)

0.561

Marital status, n (%)

    

 Married

1 (reference)

1.000

1 (reference)

1.000

 Single

1.52 (1.11–2.07)

0.009

1.60 (1.14, 2.23)

0.006

 Unknown

1.01 (0.47–2.17)

0.980

1.46 (0.66, 3.26)

0.351

Income

    

 < $60,000

1 (reference)

1.000

1 (reference)

 

 >  = $60,000

0.96 (0.70–1.33)

0.824

–

–

AJCC stage, n (%)

    

 Ib

1 (reference)

1.000

1 (reference)

1.000

 II

2.83 (1.75–4.59)

< 0.001

2.08 (0.62, 7.04)

0.238

 III

3.23 (1.85–5.64)

< 0.001

3.48 (1.00, 12.13)

0.050

 IV

6.72 (4.36–10.35)

< 0.001

5.28 (1.51, 18.46)

0.009

AJCC T, n (%)

    

 Ta

0.25 (0.03–1.81)

0.250

0.17 (0.02, 1.31)

0.090

 Tis

1.5 (0.36–6.26)

0.582

1.95 (0.46, 8.34)

0.367

 T1

1 (reference)

1.000

1 (reference)

1.000

 T2

2.93 (1.89–4.56)

< 0.001

1.69 (0.56, 5.09)

0.353

 T3

3.95 (2.44–6.40)

< 0.001

1.79 (0.57, 5.58)

0.318

 T4

5.4 (3.33–8.75)

< 0.001

1.34 (0.44, 4.13)

0.609

AJCC N, n (%)

    

 N0

1 (reference)

1.000

1 (reference)

1.000

 N1-3

3.05 (2.24–4.15)

< 0.001

0.58 (0.29, 1.15)

0.120

AJCC M, n (%)

    

 M0

1 (reference)

1.000

1 (reference)

1.000

 M1

3.92 (2.69–5.71)

< 0.001

1.49 (0.88, 2.52)

0.135

Grade

    

 I

1 (reference)

1.000

1 (reference)

 

 II

1.46 (0.13–16.10)

0.757

–

–

 III

5.45 (0.74–39.93)

0.095

–

–

 IV

6.01 (0.84–43.18)

0.075

–

–

 Unknown

6.46 (0.88–47.65)

0.067

–

–

Surgery

    

 None

1 (reference)

1.000

1 (reference)

1.000

 Local excision

0.22 (0.10–0.47)

< 0.001

0.39 (0.16, 0.96)

0.042

 Complete cystectomy

0.29 (0.13–0.63)

0.002

0.33 (0.13, 0.86)

0.024

Lymph node ratio

    

 None, Biopsy

1.88 (1.17–3.03)

0.009

2.59 (1.31, 5.12)

0.006

 < 0.061

1 (reference)

1.000

1 (reference)

1.000

 ≥ 0.061

5.22 (3.16–8.63)

< 0.001

4.13 (1.95, 8.74)

< 0.001

Radiotherapy

    

 No

1 (reference)

1.000

1 (reference)

1.000

 Yes

2.21 (1.44–3.4)

< 0.001

0.96 (0.58, 1.58)

0.863

Chemotherapy

    

 No

1 (reference)

1.000

1 (reference)

 

 Yes

1.14 (0.85–1.54)

0.385

–

–

Tumor size (mm)

    

 ≤ 31.5

1 (reference)

1.000

1 (reference)

1.000

 > 31.5

2.12 (1.41–3.19)

< 0.001

1.73 (1.12, 2.69)

0.014

 None/Unknown

1.57 (1.05–2.35)

0.027

1.49 (0.97, 2.29)

0.066

  1. Othera comprises American Indian/Alaska Native, Asian/Pacific Islander
  2. Ib comprises AJCC stage 0a, 0is, I
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us